

# Pain Management in Infants, Children, Adolescents, and Individuals with Special Health Care Needs

Revised

2022

**How to Cite:** American Academy of Pediatric Dentistry. Pain management in infants, children, adolescents, and individuals with special health care needs. The Reference Manual of Pediatric Dentistry. Chicago, Ill.: American Academy of Pediatric Dentistry; 2024:435-43.

## Abstract

*This statement provides dentists and stakeholders with current best practices for pediatric pain management. Infants, children, adolescents, and individuals with special health care needs may experience pain resulting from dental/orofacial injury, infection, and dental procedures. Dental pain is an inflammatory condition that can be categorized as somatic (i.e., periodontal, alveolar, mucosal) or visceral (i.e., pulpal). Dental professionals should consider pain assessment for all patients. Inadequate pain management may lead to significant physical and psychological consequences for patients. Perioperative pain management approaches include pre-emptive pain management (e.g., anesthetics), use of local anesthesia during general anesthesia for postoperative pain control, nonpharmacological anxiolytic interventions (e.g., providing a calm environment, emotional support), distraction and imagery (e.g., counting, video games), and pharmacological pain control agents including non-opioid analgesics (e.g., nonsteroidal anti-inflammatory drugs, acetaminophen) and opioid analgesics. Acetaminophen and nonsteroidal anti-inflammatory medications are first line pharmacologic therapies for pain management. Use of opioids for pediatric dental patients should be rare, and steps to mitigate opioid misuse are discussed.*

*This document was developed through a collaborative effort of the American Academy of Pediatric Dentistry Councils on Clinical Affairs and Scientific Affairs to offer updated information and guidance on pain management in infants, children, adolescents, and individuals with special health care needs.*

KEYWORDS: PAIN MANAGEMENT; ACUTE PAIN; CHRONIC PAIN; PAIN, POSTOPERATIVE; FACIAL PAIN; TOOTHACHE

## Purpose

The American Academy of Pediatric Dentistry (AAPD) recognizes that infants, children, adolescents, and individuals with special health care needs can and do experience pain due to dental/orofacial injury, infection, and dental procedures, and that inadequate pain management may have significant physical and psychological consequences for the patient. Appreciation of pediatric pain can help practitioners develop clinical approaches to prevent or substantially relieve dental pain. When pharmacological intervention is necessary to manage pain, the practitioner must understand the consequences, morbidities, and toxicities associated with the use of specific therapeutic agents. These recommendations are intended to provide dental professionals and other stakeholders with current best practices for pain management in pediatric dentistry.

## Methods

This document was developed by the Council on Clinical Affairs and adopted in 2018.<sup>1</sup> It is based on a review of current dental and medical literature pertaining to pain management in pediatric dental patients. Review of existing federal and professional pain management guidelines and consensus statements were used to assist with this document. An electronic search was conducted in the PubMed®/MEDLINE database using the terms: dental pain management, pediatric pain assessment, pre-emptive analgesia, paracetamol, pediatric AND

acetaminophen, adolescent AND acetaminophen, pediatric AND nonsteroidal anti-inflammatory drugs (NSAIDs), adolescent AND NSAIDs, pediatric AND opioids, adolescent AND opioids, opioid risk, adolescent orofacial pain, pediatric AND adolescent chronic pain, nonpharmacologic pain management; fields: all; limits: within the last 10 years, humans, English, systematic review, and clinical trials. There were 3,698 articles that met these criteria. Papers for review were chosen from this list and from references within selected articles. When data did not appear sufficient or were inconclusive, recommendations were based upon expert and/or consensus opinion by experienced researchers and clinicians.

## Background

Pain is defined by the International Association of the Study of Pain as “an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or

### ABBREVIATIONS

**AAP:** American Academy of Pediatrics. **AAPD:** American Academy of Pediatric Dentistry. **APAP:** Acetyl-para-aminophenol. **CDC:** Centers for Disease Control and Prevention. **CNS:** Central nervous system. **COX:** Cyclooxygenase. **FDA:** U.S. Food and Drug Administration. **IV:** Intravenous. **NSAIDs:** Nonsteroidal anti-inflammatory drugs. **U.S.:** United States. **WHO:** World Health Organization.

potential tissue damage.<sup>22</sup> Their expanded definition includes six items that provide further context to the complex topic of pain: (1) pain is always a personal experience; (2) pain is different from nociception; (3) pain is learned through life experiences; (4) a person's report of pain should be respected; (5) pain can have adverse effects on function and well-being; and (6) verbal description is one of several behaviors used to express pain.<sup>2</sup>

Intraoral pain presenting as a toothache is a common source of orofacial pain in children.<sup>3</sup> An estimated 95 percent of orofacial pain results from odontogenic causes<sup>4</sup> and, according to a recent systematic review and meta-analysis, an overall pooled prevalence of toothache in children and adolescents was 36.2 percent.<sup>3</sup> Pain experienced during dental procedures can be distressing for the provider, the child, and his parents and can also lead to difficult behavior, dental fear, and avoidance behavior in the child.<sup>5</sup> Moreover, pain experience in childhood may shape future pain experiences in adulthood.<sup>6</sup>

Pain from dental pulp arises when functional nerves are stimulated by bacteria or trauma.<sup>7</sup> Periodontal pain occurs when infectious or traumatic insults to the gingiva, periodontal ligament, and alveolar bone stimulate free nerve endings.<sup>7</sup> Other sources of orofacial pain include temporomandibular disorders (e.g., joint pain, masticatory muscle pain), headaches (e.g., migraine, tension type), or other non-odontogenic causes (e.g., pathologic jaw lesions, oral ulcers, neuralgia). Pain may be divided into diagnostic categories such as somatic, visceral, and neuropathic.<sup>8</sup> Pain encountered in dentistry is typically inflammatory and categorized as somatic (i.e., periodontal, alveolar, mucosal) or visceral (i.e., pulpal) pain.<sup>7</sup>

Pain management includes pharmacologic and nonpharmacologic strategies to treat both acute and chronic pain. Due to the increased appreciation for pediatric pain and because of the national opioid crisis, recommendations for professional education and approaches for therapeutic management are being reviewed at the national, state, and local levels.<sup>9-12</sup>

Understanding nociception (i.e., pain processing) is essential for the management of pain. Following tissue injury, infection, or invasive treatment, thermal, mechanical, and chemical stimuli activate receptors on free nerve endings in vital structures in the orofacial region.<sup>13,14</sup> In turn, sensory signals travel along afferent trigeminal nerve fibers and relay information to the brainstem and higher structures involved with the perception of pain.<sup>15</sup> Under normal conditions the perception of pain persists until the stimulus is removed.

Sensitization of central and peripheral nervous system circuits occurs following significant tissue damage or prolonged neuronal stimulation.<sup>14</sup> Terminal nerve endings at the site of tissue injury exhibit an enhanced neuronal response to noxious stimuli in the peripheral nervous system.<sup>14</sup> This local increase in nerve membrane excitability is referred to as peripheral sensitization.<sup>14</sup> The exaggerated response to stimuli in the region of tissue damage is called primary hyperalgesia.<sup>14</sup>

Central sensitization refers to enhanced functional status of pain circuits and pain processing at the level of the central nervous system (CNS).<sup>14,16,17</sup> Both secondary hyperalgesia,

which is an increase in pain intensity to noxious stimuli outside of the area of tissue damage, and allodynia, which refers to pain perception following innocuous stimuli such as light touch, are characteristics of central sensitization.<sup>17</sup> Modulation of pain pathways occurs through CNS excitatory and inhibitory processes. Ascending facilitating and descending inhibitory processes enhance or suppress the pain experience, respectively.<sup>14</sup> Both pharmacologic and nonpharmacologic methods target these processes to alter pain processing.<sup>18,19</sup>

Pain assessment is an integral component of the dental history and comprehensive evaluation. When symptoms or signs of orofacial/dental pain are evident, a detailed pain assessment helps the dentist to derive a clinical diagnosis, develop a prioritized treatment plan, and better estimate analgesic requirements for the patient. Pain is difficult to measure due to its subjectivity, especially in children<sup>5,20</sup>, and often relies on the report of parents or caregivers. In clinical practice, pain assessment is largely nonstandardized and based on signs and symptoms rather than specific tools.<sup>5</sup>

Pain can be assessed using self-report, behavioral (vocalization, facial expression, body movement), and biological (heart rate, transcutaneous oxygen, sweating, stress response) measures.<sup>21</sup> Direct questioning or a structured, comprehensive pain assessment can be clinically beneficial for pediatric and adolescent patients.<sup>21,22</sup> Conducting a structured interview begins with asking specific questions regarding pain onset, provoking factors, palliative factors, quality or character, region or location, severity or intensity, timing or duration, and impact on daily activities.<sup>23</sup> Obtaining information through self-report can be aided by asking the child to make comparisons, using temporal anchors and facilitating communication through objects or gestures.<sup>21</sup> Assessing behavioral reactions and physiological reactions to pain are required in nonverbal patients, young patients, and patients with special health care needs.<sup>21</sup> Pain experienced by children with special health care needs or developmental disabilities is more challenging to assess accurately, and assessment may benefit from the utilization of scales that rely on observations such as vocalization, facial expressions, and body movements.<sup>20</sup> Validated instruments available for assessing pain in verbal or nonverbal patients include: Wong-Baker FACES<sup>®</sup>, Faces Pain Scale (Revised), visual analogue scale (VAS), numeric rating scale (NRS), Faces, Legs, Activity, Cry, and Consolability score (FLACC), Revised Faces, Legs, Activity, Cry and Consolability (r-FLACC), and the McGill Pain Questionnaire.<sup>20,21,25</sup> Additionally, ethnic, cultural, and language factors may influence the expression and assessment of pain.<sup>26</sup>

Pain also may be categorized as acute or chronic. Acute pain that fails to respond to treatment may become chronic over time.<sup>27</sup> Chronic pain refers to pain that is dysfunctional and persists beyond the time for typical tissue healing.<sup>2,28</sup> Chronic pain is a costly public health problem that is difficult to treat.<sup>29,30</sup> Temporomandibular disorder (TMD) is an example of a chronic pain condition encountered in dentistry.<sup>31</sup>

## Pain management

### *Pre-emptive pain management*

Pre-emptive pain management refers to the administration of an anesthetic agent, medication, or technique prior to a surgical event with the goal of decreasing pain. Goals of pre-emptive pain management include attenuating central sensitization, decreasing postoperative pain, improving recovery, and reducing postoperative analgesic consumption.<sup>15,19,32,33</sup> Postoperative pain management in pediatric patients has been suboptimal in large part because parents frequently do not adequately treat pain that is experienced at home<sup>34</sup> and because of fear of adverse events.<sup>35</sup> Pain after dental treatment under general anesthesia frequently is related to the total number of teeth treated.<sup>36</sup> Nearly 50 percent of patients undergoing dental rehabilitation describe moderate to severe pain<sup>37</sup>, and data supports pre-emptive measures to optimize pain control for a variety of dental and surgical procedures.<sup>23,32,38,39</sup>

Achieving profound anesthesia prior to initiating invasive treatment decreases central sensitization.<sup>23</sup> Topical anesthetics are used in dentistry to minimize pain; yet, these medications alone may not be sufficient for dental procedures.<sup>40,41</sup> Topical anesthetics and over-the-counter products containing benzocaine have been used for minor procedures and to manage oral pain, teething, and ulcers.<sup>42</sup> However, benzocaine use in children has been linked to methemoglobinemia, a life-threatening condition.<sup>42</sup> In 2018, the United States (U.S.) Food and Drug Administration (FDA) issued a post-market warning against the use of these products for children younger than two years and that the products must have warning labels regarding methemoglobinemia.<sup>43</sup> Local anesthetic administration techniques, the anesthetic's properties, and the needle used during injection may contribute to a patient's pain experience.<sup>44</sup> Distraction techniques made at the time of the injection (e.g., jiggling the patient's cheek, applying pressure to the palate with a mirror handle) take advantage of A $\beta$ -fiber signal dominance and can significantly reduce the intensity of pain-related C-fiber signaling.<sup>44,45</sup> Buffering or decreasing acidity of local anesthetic using sodium bicarbonate can decrease injection site pain and postoperative discomfort by increasing the pH of the anesthetic.<sup>46</sup> A recent systematic review demonstrated lower pain scores following inferior alveolar block injections in children when buffered versus nonbuffered local anesthesia was used; however, there was no difference in observer-reported pain behavior.<sup>46</sup> Finally, decreasing anesthetic delivery rate also has demonstrated pain reduction during injection.<sup>47</sup>

The use of pre-emptive analgesics in conjunction with local anesthetics has been shown to increase the ability to achieve pulpal anesthesia in patients with irreversible pulpitis when compared with placebo<sup>48</sup> and to suppress the intensity of injection pain and reduce pain following extractions<sup>32,39</sup>. The pre-emptive analgesics most commonly used in dentistry are NSAIDs (e.g., ibuprofen) and acetaminophen, either alone or in combination.<sup>32</sup> Analgesics with sedative properties are often

administered during the pre-, peri-, or postoperative periods when moderate to severe pain is anticipated.<sup>49-52</sup>

### *Use of local anesthesia during general anesthesia*

Although pain is not experienced during general anesthesia, central sensitization occurs when peripheral nerves are stimulated.<sup>23,53</sup> Operating without local anesthesia may result in priming of CNS neurons and increased future pain sensitivity.<sup>6</sup> Central sensitization is minimized with pre-emptive analgesia or anesthesia. For this reason, regional block or infiltration anesthesia is commonly performed prior to surgical procedures to decrease postoperative pain.<sup>15,55</sup> However, pharmacologic and cardiac considerations, along with avoiding the numb sensation and potential for self-inflicted oral trauma, are reasons providers may choose not to provide local anesthesia during general anesthesia.<sup>55,56</sup>

### *Nonpharmacologic approaches to pain management*

Studies suggest that nonpharmacologic interventions may be effective alone or as adjuncts to pharmacological interventions in managing procedure-related pain, anxiety, and distress with minimal risk of adverse effects.<sup>57-60</sup> Fear and anxiety activate circuits within the CNS that facilitate pain.<sup>28</sup> Creating a safe, friendly environment may help a child feel more comfortable and less stressed.<sup>60,61</sup> The American Academy of Pediatrics (AAP) and the American Pain Society recommend providers reduce distress-producing stimulation and provide a calm environment for procedures to improve pain management.<sup>10</sup> Individual studies have shown the efficacy of psychological techniques, including preparation and information, parent coaching or training, suggestion, memory alteration or change, and coping self-statements.<sup>62-64</sup>

### *Distraction and imagery*

Distraction is an effective method of pain management in the pediatric population.<sup>26,65</sup> It can be cognitive (e.g., counting, nonprocedural talk) or behavioral (e.g., videos, games), both of which aim to shift attention away from pain. Distraction techniques such as bubbles, counting, conversation, music, television, toys, and video games may be used by health care providers or the child's caregiver.<sup>60,61</sup> Strong evidence supports the efficacy of distraction techniques for needle-related pain and distress in children and adolescents.<sup>66</sup> Distraction is significantly effective when measuring pulse rates, respiratory rates, and self-reported pain.<sup>10</sup> Distraction techniques may be of great use with patients with special needs who have shortened attention spans and cannot understand verbal reasoning or reassurance.<sup>62</sup> Distraction, hypnosis, combined cognitive behavior therapy (CBT), and breathing interventions have been effective in reducing children's needle-related pain or distress, or both.<sup>63</sup>

Imagery guides the child's attention away from the procedure by harnessing imagination and storytelling. Imagery in combination with distraction has been shown to decrease postoperative pain in children.<sup>65,67</sup>

### *Hypnotherapy*

Hypnotherapy aims to alter sensory experiences and dissociate from pain experiences, and hypnosis is best for children of school age or older.<sup>63,68</sup> There is evidence hypnotherapy is effective in reducing needle-related pain and distress in children and adolescents<sup>63,66,69</sup>; however, there is no evidence hypnotherapy alone is capable of producing an anesthetic effect necessary for invasive dental procedures.<sup>69</sup>

### *Virtual reality and smart phone applications*

Using digital technology can provide distraction and reduction in pain and distress for children undergoing painful procedures.<sup>70,71</sup> The use of virtual reality, video games, and smart-phone applications has shown a reduction in self-reported and observer-reported pain and distress during common procedures such as venipuncture and dental and burn treatments.<sup>70</sup> Further studies are needed to assess the benefits of distraction with a tablet compared to audiovisual glasses during dental procedures.<sup>71</sup>

### *Other techniques*

Studies have shown efficacies for pediatric pain management with other techniques such as relaxation and breathing exercises, transcutaneous electrical nerve stimulation, acupuncture, counterstimulation, video modelling, and music therapies.<sup>64,65,72-77</sup> Additional research is needed on these interventions to measure their effectiveness.<sup>76</sup>

### **Pharmacologic/therapeutic agents**

Management of pain in children is changing rapidly as a result of improvements in the appreciation of pediatric pain and pharmacologic knowledge. However, randomized controlled trials in children are lacking so the use of many pain medications is considered off label.<sup>78,79</sup> Acetaminophen and ibuprofen are recommended as first-line medication choices for the treatment of acute pain in children.<sup>26,79-81</sup> Both have been shown to have good efficacy and safety and are also cost-effective analgesics.<sup>81,82</sup> The use of opioids in children carries risks.<sup>80,83,84</sup>

### *Non-opioid analgesics*

**Nonsteroidal anti-inflammatory drugs.** NSAIDs are among the most commonly used class of drugs and have anti-inflammatory, analgesic, antipyretic, and antiplatelet properties.<sup>85</sup> They inhibit prostaglandin synthesis, with specific action on cyclooxygenase (COX), the enzyme responsible for converting arachidonic acid into pro-inflammatory mediators that drive postoperative pain, swelling, and hyperalgesia.<sup>51,83</sup> Representatives of the major categories of NSAIDs are salicylic acids (aspirin), acetic acids (ketorolac), propionic acids (ibuprofen, naproxen), and COX-2 selective inhibitor (celecoxib). Ibuprofen in oral or intravenous (IV) form is a safe and commonly used analgesic and antipyretic agent in pediatrics.<sup>81,85</sup> Ketorolac, an IV or intranasal NSAID, is useful in treating moderate to severe acute pain in patients unable or unwilling to swallow oral NSAIDs.<sup>8,53,86</sup> Some adverse

effects associated with NSAIDs include: rash, inhibition of bone growth and healing, gastritis with pain and bleeding, decreased renal blood flow and kidney dysfunction, reversible inhibition of platelet function, hepatic dysfunction, and increased incidence of cardiovascular events.<sup>8,87</sup> A specific concern with NSAIDs is the potential to exacerbate asthma due to a shift in leukotrienes.<sup>79</sup> Due to shared pathways, combined NSAIDs and corticosteroid (e.g., prednisone) use may increase the potential for gastrointestinal bleeding.<sup>88</sup>

**Acetaminophen (acetyl-para-aminophenol [APAP], paracetamol).** Acetaminophen is an analgesic with efficacy for mild to moderate pain and is an antipyretic.<sup>89</sup> Unlike NSAIDs, acetaminophen is centrally acting and does not have anti-inflammatory effects or an effect on gastric mucosal lining or platelets.<sup>89</sup> Its mechanism of action is the blockade of prostaglandin and substance P production. Allergic reactions are rare,<sup>87</sup> but toxicity from overdose may result in acute liver failure<sup>90</sup>. Acetaminophen can be administered in tablets, capsules, and liquid but also is available as oral disintegrating tablets, oral disintegrating films, and rectal and IV forms.<sup>51</sup> Rectal administration has somewhat higher bioavailability and faster onset than the oral route since it partially bypasses hepatic metabolism.<sup>91</sup>

### *Opioid analgesics*

Opioid analgesics have been used for many years to produce profound pain relief in all age groups. Opioid analgesics are considered for acute moderate to severe pain refractory to other therapies. However, opioids only interrupt the nociceptive pathway to inhibit pain perception and do not target inflammation<sup>83</sup>, which is an integral part of managing dental pain. Common uses in pediatric patients include pain associated with cancer, sickle cell disease, osteogenesis imperfecta, epidermolysis bullosa, and neuromuscular disease.<sup>92-94</sup> Limited studies are available regarding postoperative opioid use in pediatric dentistry, perhaps because pediatric dental patients rarely require opioid analgesics following dental treatment.<sup>51</sup> However, opioid/non-opioid combination medications followed by oxycodone and morphine were the most common analgesics prescribed to children during postoperative emergency room encounters.<sup>95</sup> Major concerns of opioid analgesics in the pediatric population are efficacy, safety, misuse, and accidental deaths.<sup>78,96,97</sup>

Opioids interact differentially with  $\mu$ ,  $\kappa$ , and  $\delta$  receptors in the central nervous system. Opioid agonists act on receptors located in the brain, spinal cord, and digestive tract. Activation of opioid receptors can cause respiratory depression, pupil constriction (miosis), euphoria, sedation, physical dependence, endocrine disruption, and suppression of opiate withdrawal.<sup>8</sup> Pruritus (itching) may occur due to histamine release that accompanies some opioid analgesics.<sup>49</sup> Naloxone is a  $\mu$  receptor competitive antagonist usually administered parenterally to counter opioid overdose.<sup>51</sup> Pain medicine specialists (e.g. pain physicians, anesthesiologists) are experienced in continuing,

tapering, or discontinuation of opioids in patients who are actively prescribed opioids for cancer or other pain.<sup>30,78</sup>

Codeine has more adverse effects and limited efficacy for dental pain when compared to over-the-counter analgesics.<sup>83</sup> Codeine, tramadol, and hydrocodone, and to a lesser extent oxycodone and fentanyl, are broken down in the liver to active metabolites by the highly variable cytochrome enzyme, CYP2D6.<sup>98-100</sup> Some opioid analgesics are ineffective in certain children due to poor drug metabolism.<sup>57,99</sup> Yet, other patients known as hypermetabolizers hydrolyze prodrugs to their active forms too quickly, potentially resulting in overdose, respiratory depression, and even death.<sup>98,99</sup> The FDA and AAP issued warnings and safety communications on codeine and tramadol over the past few years because of this.<sup>98,99</sup> Hydrocodone and oxycodone also rely on cytochrome p450 metabolism and have the potential for similar adverse effects.<sup>100</sup> Although systematic reviews have demonstrated that these medications provide appropriate analgesia when compared to placebo, evidence is not convincing they outperform non-opioid analgesics, and safety concerns exist.<sup>101,102</sup> In 2017, the FDA issued a warning specifically for codeine and tramadol, stating they are no longer considered safe to use in all patients less than 12 years of age.<sup>98</sup> Deaths have occurred in children using these medicines for post tonsillectomy and/or adenoidectomy pain management, general pain, sore or strep throat pain, and cold and cough.<sup>98,99</sup> The FDA warns that in the 12- through 17-year age group, these medications should not be used in high-risk patients (e.g., those with obesity, obstructive sleep apnea, lung tissue disease).<sup>98</sup> Furthermore, tramadol and codeine should not be used if breastfeeding since active metabolites are present in breast milk.<sup>98</sup>

Although morphine causes respiratory depression and histamine release, it consistently provides rapid relief of severe pain for two to three hours.<sup>8</sup> To that point, the potency of all opioids is compared to morphine using a morphine milligram equivalent dose.<sup>8</sup> Considering the variability of drug metabolism, safety concerns, and the experience of pain, the “right dose” for everyone does not exist.<sup>8</sup> For example, fentanyl is 100 times more potent than morphine, ultra-short acting, and used for invasive procedures and sedations.<sup>8</sup> Chest wall rigidity is a well-known adverse reaction to fentanyl.<sup>8</sup> Rapidly-acting oxycodone has a longer half-life than morphine and is more potent.<sup>8</sup> Oxycodone is available as a single agent or is combined with aspirin, ibuprofen, or acetaminophen. It comes in tablets, capsules, oral solution, and oral concentrate, and use is considered off label in children.<sup>51,95</sup>

**Opioid concerns and Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) recommendations.** Trends in opioid overdose, opioid misuse, and concerns for opioid addiction prompted the CDC and the WHO to issue guidelines for prescribing opioids for chronic pain.<sup>103</sup> The CDC guideline focuses on adults while the WHO guideline relates specifically to children.<sup>103</sup> Although chronic pain is the focus of the guidelines, both aims

to improve prescribing practices and to ultimately benefit patient safety, emotional well-being, and quality of life.<sup>30,103,104</sup> The topics covered in the guidelines include limiting opioids for moderate to severe pain, restricting opioid prescriptions to three days, providing concurrent pharmacologic and non-pharmacologic therapy, and following accepted protocols for procurement, storage, and disposal of unused opioids.<sup>30,103</sup> The CDC guideline also advises against overlapping benzodiazepines and opioids prescriptions because of the increased potential for respiratory depression.<sup>103</sup>

Deaths due to opioid overdoses reached record highs and prompted the CDC to declare an opioid epidemic in 2011.<sup>97,105</sup> The pediatric mortality rate for opioid poisoning increased nearly threefold from 1999 to 2016, with nearly 9,000 children and adolescents in the United States dying as a result of opioids.<sup>105</sup> A trend towards increased pediatric emergency department visits due to opioid ingestion and a greater than five-fold increase in overdose death rates in the 15-24-year age group also have been demonstrated.<sup>105</sup> Risky use of opioids among children and adolescents is a growing trend, and the concern for opioid use disorder in adolescents is significant.<sup>106,107</sup> Since commercial opioids often are combined with acetaminophen, the potential for hepatotoxicity is an accompanying concern.<sup>90</sup> In 2016, the AAP released a policy statement that recommended timely intervention to curb opioid use disorder with the goal of eliminating long-term medical, psychiatric, and social consequences of ongoing substance abuse.<sup>99</sup>

Opioid risk mitigation involves recognizing drug-seeking behavior.<sup>9</sup> To address the potential risk of opioid misuse, screening patients prior to prescribing opioids has been advocated as standard practice.<sup>103</sup> However, a standardized assessment for adolescents has not been identified.<sup>78,108</sup> Therefore, at a minimum, a thorough review of medical history including analgesics used in the past is indicated before prescribing.<sup>78</sup> Despite the fact that screening of parents is recommended by the AAP, this is not a common practice.<sup>109,110</sup> Nonetheless, screening is essential for identifying children at risk of opioid exposure in the home. Children of parents who abuse opioids are at an increased risk for neglect and often suffer from parental instability and lack of structure in the home.<sup>110</sup>

For professionals who suspect patients have misuse issues, the FDA, National Institutes of Health, National Institute on Drug Abuse, the American Dental Association, and state prescription drug monitoring programs have resources available to review the history of prescriptions for controlled substances which may decrease their diversion.<sup>111</sup> Transparent discussion about the potential for physical and/or psychological dependence is a critical component of safe opioid practices in the adolescent population.<sup>80,112</sup> Furthermore, discussion regarding the proper disposal of unused controlled medications is key to reducing availability/diversion of opioids.<sup>80,112</sup> Safeguarding of opioids stored in offices for sedation can be accomplished by following security requirements for dispensers of controlled substances.<sup>113</sup>

## Recommendations

Infants, children, and adolescents can and do experience pain due to dental/orofacial injury, infection, and dental procedures. Inadequate pain management may have significant physical and psychological consequences for the patient. Adherence to the following recommendations can help practitioners prevent or substantially relieve pediatric dental pain and minimize risk of associated morbidities. Practitioners should:

1. assess pain for all patients as part of the dental history.
2. avoid sensitization by using techniques to minimize stimulation and tissue damage when providing dental treatment.
3. achieve profound anesthesia prior to invasive treatment.
4. use pre-emptive analgesia when moderate to severe post-operative pain is anticipated.
5. manage odontogenic and non-odontogenic pain with combined nonpharmacologic (e.g., distraction) and pharmacologic pain management.
6. use APAP/NSAIDs as first-line pharmacologic therapy for pain management.
7. use caution and carefully assess benefits and risks of adverse events when considering prescribing opioids for pain management in children and adolescents.
8. minimize the risk of opioid misuse by screening patients and parents regarding previous/current opioid use before prescribing opioid analgesics.
9. utilize prescription monitoring databases and inform parents to properly discard unused medications to avoid diversion of controlled substances.
10. inform parents of risks associated with prescribed and over-the-counter analgesic medications and anticipate and manage adverse effects (e.g., asthma and NSAIDs, sedation and opioids.)
11. seek expert consultation for patients with chronic pain or other complicated pain condition.
12. be familiar with analgesic properties of agents when used in conjunction with sedation or general anesthesia.
13. strongly advise against opioids in high-risk patients (e.g., obesity, obstructive sleep apnea, lung tissue disease, benzodiazepines use).
14. use an alternating schedule of APAP and NSAIDs for multimodal pain management if single-agent therapy is ineffective.

## References

1. American Academy of Pediatric Dentistry. Pain management in infants, children, adolescents, and individuals with special health care needs. *Pediatr Dent* 2018;40(6):321-9.
2. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: Concepts, challenges, and compromises. *Pain* 2020;161(9):1976-82.
3. Santos PS, Barasuol JC, Moccellini BS, et al. Prevalence of toothache and associated factors in children and adolescents: A systematic review and meta-analysis. *Clin Oral Investig* 2022;26(2):1105-19.
4. Tecco S, Ballanti F, Baldini A. New frontiers in orofacial pain and its management. *Pain Res Manag* 2018;2018:6286717.
5. Randall CL, Zahlis E, Chi DL. Pediatric dental procedure-related pain assessment practices in a rural Alaskan healthcare organization: A qualitative study. *Pediatr Dent* 2020;42(5):350-3.
6. Baccei ML, Fitzgerald M. Development of pain pathways and mechanisms. In: McMahon SB, Koltzenburg M, Tracey I, Turk DC, eds. *Wall and Melzack's Textbook of Pain*. 6th ed. Philadelphia, Pa.: Elsevier Saunders; 2013:143-55.
7. de Leeuw R, Klasser G. *American Academy of Orofacial Pain: Guidelines for Assessment, Diagnosis and Management*. 6th ed. Hanover, Ill.: Quintessence Publishing; 2018:121-42.
8. Zeltzer LK, Krane EJ, Palermo TM. Pediatric pain management. In: Kliegman RM, Stanton BF, St. Geme JW, Blum NJ, eds. *Nelson's Textbook of Pediatrics*. 21st ed. Philadelphia, Pa.: Elsevier Saunders; 2019:469-90.
9. Shaefer J, Barreveld AM, Arnstein P, Kulich RJ. Inter-professional education for the dentist in managing acute and chronic pain. *Dent Clin North Am* 2016;60(4):825-42.
10. American Academy of Pediatrics, American Pain Society. The assessment and management of acute pain in infants, children and adolescents. *Pediatrics* 2001;108(3):793-7.
11. Association of Paediatric Anaesthetists of Great Britain and Ireland. *Good practice in postoperative and procedural pain management*, 2nd ed. *Paediatr Anaesth* 2012;22(Suppl 1):1-79.
12. Pogatzki-Zahn EM, Zahn PK, Brennan TJ. Postoperative pain-clinical implications of basic research. *Best Prac Res Clin Anaesthesiol* 2007;21(1):3-13.
13. Dawes MM, Andersson DA, Bennett DLH, Bevan S, McMahon SB. Inflammatory mediators and modulators of pain. In: McMahon SB, Koltzenburg M, Tracey I, Turk DC, eds. *Wall and Melzack's Textbook of Pain*. 6th ed. Philadelphia, Pa.: Elsevier Saunders; 2013:48-67.
14. Latremoliere A, Woolf CJ. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. *J Pain* 2009;10(9):895-926.
15. Kaufman E, Epstein JB, Gorsky M, Jackson DL, Kadari A. Preemptive analgesia and local anesthesia as a supplement to general anesthesia: A review. *Anesth Prog* 2005;52(1):29-38.
16. Brennan TJ. Pathophysiology of postoperative pain. *Pain* 2011;152(3):S33-40.
17. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. *Pain* 2011;152(3 Suppl):S2-15.
18. Stinson J, Connelly M, Kamper SJ, et al. Models of care for addressing chronic musculoskeletal pain and health in children and adolescents. *Best Prac Res Clin Rheumatol* 2016;30(3):468-82.
19. Buvanendran A, Lubenow TR, Krooni JS. Postoperative pain and its management. In: McMahon SB, Koltzenburg M, Tracey I, Turk DC, eds. *Wall and Melzack's Textbook of Pain*. 6th ed. Philadelphia, Pa.: Elsevier Saunders; 2013:629-44.
20. Jain A, Yeluri R, Munshi AK. Measurement and assessment of pain in children – A review. *J Clin Pediatr Dent* 2012;37(2):125-36.
21. McGrath PJ, Unruh AM. Measurement and assessment of pediatric pain. In: McMahon SB, Koltzenburg M, Tracey I, Turk DC, eds. *Wall and Melzack's Textbook of Pain*. 6th ed. Philadelphia, Pa.: Elsevier Saunders; 2013:320-7.
22. Gouri AJ, Jaju RA, Tate A. The practice and perception of pain assessment in US pediatric dentistry residency programs. *Pediatr Dent* 2010;32(7):546-50.

23. Chou, R, Gordon, DB, de Leon-Cassola OA, et al. Management of postoperative pain: A clinical practice guideline from the American Pain Society, American Society of Regional Anesthesia and Pain Medicine, American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Counsel. *J Pain* 2016;17(2):131-57.
24. McGrath PJ, Walco GA, Turk DC, et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. *J Pain* 2008;9(9):771-83.
25. Hauer J, Jones BL. Evaluation and management of pain in children. Poplack DG, Armsby C, eds. *UpToDate*. Waltham, Mass.: UpToDate Inc; 2021. Available at: "https://www.uptodate.com/contents/evaluation-and-management-of-pain-in-children?search=.%20Evaluation%20and%20management%20of%20pain%20in%20children&source=search\_result&selectedTitle=1-150&usage\_type=default&display\_rank=1". Accessed August 25, 2022.
26. Lee GY, Yamada J, Kyolo O, Shorkey A, Stevens B. Pediatric clinical practice guidelines for acute procedural pain: A systematic review. *Pediatrics* 2014;133(3):500-15.
27. Batoz H, Semjen F, Bordes-Demolis M, Bénard A, Nouette-Gaulain K. Chronic postsurgical pain in children: Prevalence and risk factors. A prospective observational study. *Br J Anaesth* 2016;117(4):489-96.
28. Palmero T, Eccleston C, Goldschneider K, et al. Assessment and management of children with chronic pain: Position statement from the American Pain Society. Chicago, Ill.: American Pain Society; 2012:1-4. Available at: "https://da7648.approby.com/m/3063bf5632bf22e3.pdf". Accessed September 12, 2022.
29. Gewandter JS, Dworkin RH, Turk DC, et al. Research design considerations for chronic pain prevention in clinical trials: IMMPACT recommendations. *Pain* 2015;156(7):1184-97.
30. World Health Organization. Guidelines on the management of chronic pain in children. Geneva: World Health Organization; 2020. License: CC BY-NCSA3.0 IGO. Available at: "https://www.who.int/publications/i/item/9789240017870". Accessed August 25, 2022.
31. American Academy of Pediatric Dentistry. Acquired temporomandibular disorders in infants, children, and adolescents. *The Reference Manual of Pediatric Dentistry*. Chicago, Ill.: American Academy of Pediatric Dentistry; 2022:442-50.
32. Raslan N, Zouzou T. Comparison of preemptive ibuprofen, acetaminophen, and placebo administration in reducing peri- and postoperative pain in primary tooth extraction: A randomized clinical trial. *Clin Exp Dent Res* 2021;7(6):1045-52.
33. Ashley PF, Parekh S, Moles DR, Anand P, MacDonald LC. Preoperative analgesics for additional pain relief in children and adolescents having dental treatment. *Cochrane Database Syst Rev* 2016;(8):CD008392. Available at: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568367/". Accessed September 12, 2022.
34. Rony RYZ, Fortier MA, Chorney JM, Perret D, Kain ZN. Parental postoperative pain management: Attitudes, assessment, and management. *Pediatrics* 2010;125(6):e1372-8.
35. Finley GA, Franck LS, Grunau RE, von Baeyer CL. Why children's pain matters. *Pain: Clin Updates* 2005;13(4):1-6.
36. Hu Y-H, Tsai A, Ou-Yang L-W, Chuang L-C, Chang P-C. Postoperative dental morbidity in children following dental treatment under general anesthesia. *BMC Oral Health* 2018;18(1):84.
37. Wong M, Copp PE, Haas DA. Postoperative pain in children after dentistry under general anesthesia. *Anesth Prog* 2015;62(4):140-52.
38. Kaye AD, Helander EM, Vadivelu N, et al. Consensus statement for clinical pathway development or perioperative pain management and pain care transitions. *Pain Ther* 2017;6(2):129-41.
39. Kharouba J, Ratson T, Somri M, et al. Preemptive analgesia by paracetamol, ibuprofen, or placebo in pediatric dental care. A randomized controlled study. *J Clin Pediatr Dent* 2019;43(1):51-5.
40. Boyce RA, Kirpalani T, Mohan N. Updates of topical and local anesthesia agents. *Dent Clin North Am* 2016;60(2):445-71.
41. Shavit I, Peri-Front Y, Rosen-Walther A, et al. A randomized trial to evaluate the effect of two topical anesthetics on pain response during frenotomy in young infants. *Pain Med* 2017;18(2):356-62.
42. Gutenberg LL, Chen JW, Trapp L. Methemoglobin levels in generally anesthetized pediatric dental patients receiving prilocaine versus lidocaine. *Anesth Prog* 2013;60(3):99-108.
43. U.S. Food and Drug Administration. Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics. Available at: "https://www.fda.gov/drugs/drug-safety-and-availability/risk-serious-and-potentially-fatal-blood-disorder-prompts-fda-action-oral-over-counter-benzocaine". Accessed August 25, 2022.
44. Glass JS, Hardy CL, Meeks NM, Carrol BT. Acute pain management in dermatology: Risk assessment and treatment. *J Am Acad Dermatol* 2015;73(4):543-60.
45. Malamed SF, Tavana S, Falkel M. Faster onset and more comfortable injection with alkalized 2% lidocaine with epinephrine 1:100,000. *Compend Contin Educ Dent* 2013;34(1):10-20.
46. Tirupathi SP, Rajasekhar S. Buffered versus unbuffered local anesthesia for inferior alveolar nerve block injections in children: A systematic review. *J Dent Anesth Pain Med* 2020;20(5):271-9.
47. Garret-Bernardin A, Cantile T, D'Antò V. Pain experience and behavior management in pediatric dentistry: A comparison between traditional local anesthesia and the wand computerized delivery system. *Pain Res Manag* 2017;2017:1-6.
48. Shirvani A, Shamszadeh S, Enghbal MJ, Marvasti LA, Asgary S. Effect of preoperative oral analgesics on pulpal anesthesia in patients with irreversible pulpitis—A systematic review and meta-analysis. *Clin Oral Investig* 2017;21(1):43-52.
49. Pacheco GS, Ferayorni A. Pediatric procedural sedation and analgesia. *Emerg Med Clin North Am* 2013;31(3):831-52.
50. American Academy of Pediatric Dentistry. Use of nitrous oxide for pediatric dental patients. *The Reference Manual of Pediatric Dentistry*. Chicago, Ill.: American Academy of Pediatric Dentistry; 2022:353-8.

*References continued on the next page.*

51. Laskarides C. Update on analgesic medication for adult and pediatric dental patients. *Dent Clin North Am* 2016; 60(2):347-66.
52. Conner ER, Musser D, Colpitts KM, Laochamroonvorapongse DL, Koh JL. Perioperative opioid administration in children with and without developmental delay undergoing out-patient dental surgery. *J Clin Anesth* 2017;37:92-6.
53. Keles S, Kocaturk O. Immediate postoperative pain and recovery time after pulpotomy performed under general anaesthesia in young children. *Pain Res Manag* 2017;2017: 9781501.
54. Townsend JA, Ganzberg S, Thikkurissy S. The effect of local anesthetic on quality of recovery characteristics following dental rehabilitation under general anesthesia in children. *Anesth Prog* 2009;56(4):115-22.
55. American Academy of Pediatric Dentistry. Use of local anesthesia for pediatric dental patients. *The Reference Manual of Pediatric Dentistry*. Chicago, Ill.: American Academy of Pediatric Dentistry; 2022:347-52.
56. Parekh S, Gardener C, Ashley PF, Walsh T. Intraoperative local anaesthesia for reduction of postoperative pain following general anaesthesia for dental treatment in children and adolescents. *Cochrane Database Syst Rev* 2014;(12): CD009742. Available at: "<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669268/>". Accessed September 12, 2022.
57. Dostrovsky JO. Inflammatory and cancer-related orofacial pain mechanisms: Insight from animal models. In: Sessel BJ, ed. *Orofacial Pain: Recent Advancements in Assessment, Management, and Understanding of Mechanisms*. Washington, D.C.: International Association for the Study of Pain Press; 2014:305-30.
58. Landier WN, Tse A. Use of complementary and alternative medical interventions for the management of procedure-related pain, anxiety, and distress in pediatric oncology: An integrative review. *J Pediatr Nurs* 2010;25(6):566-79.
59. Lewin D, Dahl R. Importance of sleep in the management of pediatric pain. *J Devel Beh Pediatrics* 1999;20(4): 244-52.
60. Fein A, Zempsky WT, Cravero JP. Relief of pain and anxiety in pediatric patient in emergency medical systems. *Pediatrics* 2012;130(5):e1391-405.
61. Ruest S, Anderson A. Management of acute pediatric pain in the emergency department. *Curr Opin Pediatr* 2016;28 (3):298-304.
62. Lyons RA. Understanding basic behavioral support techniques as an alternative to sedation and anesthesia. *Spec Care Dent* 2009;29(1):39-50.
63. Birnie KA, Noel M, Chambers CT, Uman LS, Parker JA. Psychological interventions for needle-related procedural pain and distress in children and adolescents. *Cochrane Database Syst Rev* 2018;10:CD005179. Available at: "<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517234/>". Accessed September 12, 2022.
64. Goettems ML, Zborowski EJ, Costa FC, et al. Non-pharmacologic intervention on the prevention of pain and anxiety during pediatric dental care: A systematic review. *Acad Pediatr* 2017;17(2):110-9.
65. Davidson F, Snow S, Haydenc J, Chorney J. Psychological interventions in managing postoperative pain in children: A systematic review. *Pain* 2016;157(9):1872-86.
66. Uman LS, Birnie KA, Noel M, et al. Psychological interventions for needle-related procedural pain and distress in children and adolescents. *Cochrane Database Syst Rev* 2013;(10):CD005179.
67. Bukola IM, Paula D. The effectiveness of distraction as procedural pain management technique in paediatric oncology patients: A meta-analysis and systematic review. *J Pain Symptom Manag* 2017;54(4):589-600.
68. Kohen DP, Kaiser P. Clinical hypnosis with children and adolescents – What? Why? How?: Origins, applications, and efficacy. *Children (Basel)* 2014;1(2):74-98.
69. Ramírez-Carrasco A, Butrón-Téllez Girón C, Sanchez-Armass O, Pierdant-Pérez M. Effectiveness of hypnosis in combination with conventional techniques of behavior management in anxiety/pain reduction during dental anesthetic infiltration. *Pain Res Manag* 2017;2017:1434015.
70. Gates M, Hartling L, Shulhan-Kilroy J, et al. Digital technology distraction for acute pain in children: A meta-analysis. *Pediatrics* 2020;145(2):e20191139.
71. Cunningham A, McPolin O, Fallis R, Coyle C, Best P, McKenna G. A systematic review of the use of virtual reality or dental smartphone applications as interventions for management of paediatric dental anxiety. *BMC Oral Health* 2021;21(1):244.
72. Eccleston C, Palmero TM, Williams ACDC, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. *Cochrane Database of Syst Rev* 2014;(5):CD003968. Available at: "<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886855/>". Accessed September 12, 2022.
73. Brown ML, Rojas E, Gouda S. A mind-body approach to pediatric pain management. *Children* 2017;4(6):50. Available at: "<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483625/>". Accessed July 1, 2022.
74. Munshi AK, Hegde AM, Girdhar D. Clinical evaluation of electronic dental anesthesia for various procedures in pediatric dentistry. *J Clin Pediatr Dent* 2000;24(3):199-204.
75. Kasat V, Gupta A, Ladd R, Kathariya M, Saluja H, Farooqui AA. Transcutaneous electric nerve stimulation (TENS) in dentistry – A review. *J Clin Exp Dent* 2014;6(5):e562-8.
76. Monteiro J, Tanday A, Ashley PF, Parekh S, Alamri H. Interventions for increasing acceptance of local anaesthetic in children and adolescents having dental treatment. *Cochrane Database Syst Rev* 2020;2(2):CD011024. Available at: "<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045283/>". Accessed September 12, 2022.
77. Klassen JA, Liang Y, Tjosvold L, et al. Music for pain and anxiety in children undergoing medical procedures: A systematic review of randomized controlled trials. *Ambul Pediatr* 2008;8(2):117-28.
78. Walco GA, Gove N, Phillips J, Weisman SJ. Opioid analgesics administered for pain in the inpatient pediatric setting. *J Pain* 2017;18(10):1270-6.
79. Hartling L, Ali S, Dryden DM, et al. How safe are common analgesics for the treatment of acute pain for children? A systematic review. *Pain Res Manag* 2016;2016:5346819.
80. Kelley-Quon LI, Kirkpatrick MG, Ricca RL, Baird R, Harbaugh CM. Guidelines for opioid prescribing in children and adolescents after surgery: An expert panel opinion. *JAMA Surg* 2020;156(1):76-90.
81. Koh SWC, Li CF, Loh JSP, Wong ML, Loh VWK. Managing tooth pain in general practice. *Singapore Med J* 2019;60(5):224-8.
82. Timmerman A, Parashos P. Management of dental pain in primary care. *Aust Prescr* 2020;43(2):39-44.
83. Teoh L. Managing acute dental pain without codeine. *Aust Prescr* 2020;43(2):64.

84. Scrivani SJ, Keith DA, Kulich RJ, et al. Pain management for dental medicine in 2021: Opioids, coronavirus and beyond. *J Pain* 2021;14:1371-87.
85. Vittinghoff M, Lönnqvist PA, Mossetti V, et al. Post-operative pain management in children: Guidance from the pain committee of the European Society for Paediatric Anaesthesiology (ESPA Pain Management Ladder Initiative). *Paediatr Anaesth* 2018;28(6):493-506.
86. Neri E, Maestro A, Minen F, et al. Sublingual ketorolac versus sublingual tramadol for moderate to severe post-traumatic bone pain in children: A double-blind, randomized, controlled trial. *Arch Dis Child* 2013;98(9):721-4.
87. Gosnell ES, Thikkurissy S. Assessment and management of pain in the pediatric patient. In: Nowak AJ, Christensen JR, Mabry, TR, Townsend JA, Wells MH, eds. *Pediatric Dentistry: Infancy through Adolescence*. 6th ed. St. Louis, Mo.: Elsevier; 2019:97-115.
88. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. *Ther Clin Risk Manag* 2015;15(11):1061-75.
89. Becker DE. Pain management: Part 1: Managing acute and postoperative dental pain. *Anesth Prog* 2010;57(2):67-80.
90. Drew S. Best practices for management of pain, swelling, nausea, and vomiting in dentoalveolar surgery. *Oral Maxillofac Surg Clin North Am* 2015;27(3):393-404.
91. Shah R, Sawardekar A, Suresh A. Pediatric acute pain management. In: Benzon HT, Rathmell JP, Wu CL, Turk DC, Argoff CE, Hurley RW, eds. *Practical Management of Pain*. 5th ed. Philadelphia, Pa.: Elsevier Inc.; 2014:304-11.
92. Schechter JL, Waldo GA. The potential impact on children of the CDC guidelines for prescribing opioids for chronic pain: Above all, do no harm. *JAMA Pediatr* 2016;170(5):425-6.
93. Cooper TE, Wiffen PJ, Heathcote LC, et al. Antiepileptic drugs for chronic non-cancer pain in children and adolescents. *Cochrane Database of Syst Rev* 2017;8(8):CD012536. Available at: "<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424379/>". Accessed July 1, 2022.
94. Fortuna RJ, Robbins BW, Cajola E, et al. Prescribing of controlled medications to adolescents and young adults in the United States. *Pediatrics* 2010;126(6):1108-16.
95. Stake CE, Manworren RCB, Rizeq YK, et al. Use of opioids and nonopioid analgesics to treat pediatric postoperative pain in the emergency department. *Pediatr Emerg Care* 2022;1(38):e234-9.
96. Van Cleve WC, Grigg EB. Variability in opioid prescribing for children undergoing ambulatory surgery in the United States. *J Clin Anesth* 2017;41:16-20.
97. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths – United States, 2010-2015. *Morb Mortal Wkly Rep* 2016;65(50-51):1445-52.
98. U.S. Food and Drug Administration. Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. Available at: "<https://www.fda.gov/downloads/Drugs/DrugSafety/UCM553814.pdf>". Accessed February 4, 2022.
99. Tobias JD, Green TP, Coté CJ; Section on Anesthesiology and Pain Medicine; Committee on Drugs. Codeine: Time to say "no". *Pediatrics* 2016;138(4):e20162396.
100. Crews KR, Monte AA, Huddart R, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. *Clin Pharmacol Ther* 2021;110(4):888-96.
101. Schnabel A, Reichl SU, Meyer-Frießem C, Zahn PK, Pogatzki-Zahn E. Tramadol for postoperative pain treatment in children. *Cochrane Database Syst Rev* 2015;(3):CD009574. Available at: "<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464560/>". Accessed September 28, 2022.
102. Dancel R, Liles EA, Fiore D. Acute pain management in hospitalized children. *Rev Recent Clin Trials* 2017;12(4):277-83.
103. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. *MMWR Recomm Rep* 2016;65(No. RR-1):1-49.
104. Tompkins DA, Hobelmann JG, Compton P. Providing chronic pain management in the 5th vital sign era: Historical and treatment perspectives in a modern-day medical dilemma. *Drug Alcohol Depend* 2017;173(Suppl 1):S11-21.
105. DePhillips M, Watts J, Lowry J, Dowdy MD. Opioid prescribing practices in pediatric acute care settings. *Pediatr Emerg Care* 2019;35(1):16-21.
106. Allareddy V, Rampa S, Allareddy V. Opioid abuse in children: An emerging public health crisis in the United States! *Pediatr Res* 2017;82(4):562-3.
107. McCabe SE, West BT, Veliz P, et al. Trends in medical and nonmedical use of prescription opioids among U.S. adolescents: 1976-2015. *Pediatrics* 2017;139(4):e20162387.
108. Smith SM, Paillard F, McKeown A, et al. Instruments to identify prescription medication misuse, abuse, and related events in clinical trials: An ACTION systematic review. *J Pain* 2015;16(5):389-411.
109. Lane WG, Dubowitz H, Feigelman S, et al. Screening for parental substance abuse in pediatric primary care. *Ambul Pediatr* 2007;7(6):458-62.
110. Spehr MK, Coddington J, Ahmed A, Jones E. Parental opioid abuse: Barriers to care, policy, and implications for primary care pediatric providers. *J Pediatr Healthcare* 2017;31(6):695-702.
111. National Institute of Health, National Institute on Drug Abuse. Principles of adolescent substance use disorder treatment: A research-based guide. NIH Publication Number 14-7953. January, 2014. Available at: "<https://nida.nih.gov/publications/principles-adolescent-substance-use-disorder-treatment-research-based-guide/principles-adolescent-substance-use-disorder-treatment>". Accessed February 5, 2022.
112. American Academy of Pediatric Dentistry. Policy on substance misuse in adolescent patients. *The Reference Manual of Pediatric Dentistry*. Chicago, Ill.: American Academy of Pediatric Dentistry; 2022:112-6.
113. Code of Federal Regulations (CFR) Title 21. Volume 9, Chapter 2, Part 1303. Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances. 2022. Available at: "<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1301.75>". Accessed on March 13, 2022.